InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

NCT04379076 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Stopped POOR ACCRUAL

Conditions

COVID-19
Lymphocytopenia

Interventions

DRUG: Interleukin-7
DRUG: Placebos

Sponsor

Revimmune

Collaborators

[object Object]